A recent move by US FDA clarifies protections for manufacturers that might want to discuss a device treatment regimen with an insurance company, or share suggestions about device usage that aren’t included in the labeling with physicians.
The agency announced June 12 that it finalized two question-and-answer format guidance documents related to manufacturer communications. The first addresses...
Welcome to Medtech Insight
Create an account to read this article
Already a subscriber?